non-small cell lung cancer

J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
Reuters
JNJ
non-small cell lung cancer
AstraZeneca
Rybrevant
lazertinib
Tagrisso
Flag link:
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
BioPharma Dive
Bristol Myers Squibb
Opdivo
non-small cell lung cancer
clinical trials
Flag link:
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Clinical Trials Arena
Gilead Sciences
Trodelvy
TROP-2
non-small cell lung cancer
Flag link:
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
melanoma
colorectal cancer
non-small cell lung cancer
Flag link:
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
non-small cell lung cancer
Dato-DXd
Flag link:
WCLC: Tagrisso's chemo combo shows edge, but AstraZeneca thinks monotherapy remains king in lung cancer
WCLC: Tagrisso's chemo combo shows edge, but AstraZeneca thinks monotherapy remains king in lung cancer
Fierce Pharma
AstraZeneca
Tagrisso
non-small cell lung cancer
Flag link:
Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients
Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients
Clinical Trials Arena
Mirati Therapeutics
non-small cell lung cancer
Krazati
clinical trials
Flag link:
Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up
Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up
Fierce Biotech
Roche
Tigit
clinical trials
lung cancer
non-small cell lung cancer
tiragolumab
Flag link:
FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset
FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset
Cure Today
Genentech
Blueprint Medicines
Gavreto
non-small cell lung cancer
Flag link:
Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC
Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC
Clinical Trials Arena
Eli Lilly
clinical trials
Retevmo
non-small cell lung cancer
Keytruda
Flag link:
Hummingbird begins Phase Ib trials of HMBD-001 in Australia
Hummingbird begins Phase Ib trials of HMBD-001 in Australia
Clinical Trials Arena
Hummingbird Bioscience
clinical trials
HMBD-001
squamous non-small cell lung carcinoma
non-small cell lung cancer
Flag link:
J&J touts Rybrevant win in newly diagnosed lung cancer, with key Tagrisso head-to-head readout up next
J&J touts Rybrevant win in newly diagnosed lung cancer, with key Tagrisso head-to-head readout up next
Fierce Pharma
JNJ
Rybrevant
non-small cell lung cancer
Takeda
Tagrisso
Flag link:
Iovance looks to advance its non-small cell lung cancer therapy
Iovance looks to advance its non-small cell lung cancer therapy
Clinical Trials Arena
Iovance Biotherapeutics
clinical trials
tumor-infiltrating lymphocyte therapy
non-small cell lung cancer
lifileucel
Flag link:
AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
Enhertu
clinical trials
non-small cell lung cancer
Flag link:
9 Highly Anticipated FDA Decisions in Second Half of 2023
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Flag link:
FDA approves Biostar’s Phase II/III plans with utidelone injectable for NSCLC
FDA approves Biostar’s Phase II/III plans with utidelone injectable for NSCLC
Clinical Trials Arena
Biostar
FDA
utidelone
UTD1
non-small cell lung cancer
Flag link:
This Drug Candidate Could Be a Winner for Bristol Myers
This Drug Candidate Could Be a Winner for Bristol Myers
Motley Fool
Bristol Myers Squibb
repotrectinib
non-small cell lung cancer
metastatic small cell lung cancer
Flag link:
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
BioSpace
ASCO 2023
oncologists
cancer
AstraZeneca
Tagrisso
non-small cell lung cancer
Novartis
Kisqali
breast cancer
Merck
Keytruda
Moderna Therapeutics
cancer vaccine
Flag link:
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
EP Vantage
ASCO 2023
Daiichi Sankyo
AstraZeneca
datopotamab deruxtecan
non-small cell lung cancer
Flag link:
ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
Clinical Trials Arena
ASCO 2023
AstraZeneca
clinical trials
non-small cell lung cancer
rilvegostomig
Flag link:

Pages